 |
|
Vitrectomy Combined with Intraoperative Dexamethasone Implant for the Management of Refractory Diabetic Macular Edema
Kyung Tae Kim, Jun Won Jang, Se Woong Kang, Ju Byung Chae, Kyuyeon Cho, Kunho Bae
Korean J Ophthalmol. 2019;33(3):249-258. Published online 2019 Jun 4 DOI: https://doi.org/10.3341/kjo.2018.0100
|
|
Citations to this article as recorded by
 Mid-term safety and effectiveness of macular peeling one month after intravitreal dexamethasone implant for tractional diabetic macular edema
Francesco Pignatelli, Alfredo Niro, Matteo Fallico, Fedele Passidomo, Samuele Gigliola, Annalisa Nacucchi, Vincenza Bonfiglio, Michele Reibaldi, Giuseppe Addabbo, Teresio Avitabile
Scientific Reports.2023;[Epub] CrossRef Three-year outcomes of vitrectomy combined with intraoperative dexamethasone implantation for non-tractional refractory diabetic macular edema
Sungsoon Hwang, Se Woong Kang, Kyung Tae Kim, Hoon Noh, Sang Jin Kim
Scientific Reports.2021;[Epub] CrossRef Pharmacotherapy as an adjunct to vitrectomy
Victor M. Villegas, Mónica P. González, Audina M. Berrocal, Timothy G. Murray
Therapeutic Advances in Ophthalmology.2021; 13: 251584142110161. CrossRef Intravitreal Dexamethasone Implant as a Sustained Release Drug Delivery Device for the Treatment of Ocular Diseases: A Comprehensive Review of the Literature
Claudio Iovino, Rodolfo Mastropasqua, Marco Lupidi, Daniela Bacherini, Marco Pellegrini, Federico Bernabei, Enrico Borrelli, Riccardo Sacconi, Adriano Carnevali, Rossella D’Aloisio, Alessio Cerquaglia, Lucia Finocchio, Andrea Govetto, Stefano Erba, Giacin
Pharmaceutics.2020; 12(8): 703. CrossRef
|